BiotechTube

Thrombolytic therapy

Pre-clinicalUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

— → —

NCT ID
NCT00136929

About Thrombolytic therapy

Thrombolytic therapy is a pre-clinical stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT00136929. Target conditions include Myocardial Infarction.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction were approved

Approved (20) Terminated (3) Active (0)
✅AbciximabEli LillyApproved
✅AbciximabEli LillyApproved
✅abciximabEli LillyApproved
✅Ticagrelor + ClopidogrelAstraZenecaApproved
✅ticagrelor + aspirinAstraZenecaApproved
✅Ticagrelor + PlaceboAstraZenecaApproved
✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00136929Pre-clinicalUNKNOWN

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
AbciximabEli LillyApproved
43
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
40
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
35
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
18
No interventionAstellas PharmaPre-clinical
22
Empagliflozin + PlaceboEli LillyPhase 3
40
Abciximab + Abciximab placeboEli LillyPhase 3
36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
40
AbciximabEli LillyApproved
43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
40
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
40
abciximabEli LillyApproved
43
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
38
TicagrelorAstraZenecaPre-clinical
26
TicagrelorAstraZenecaPhase 2
31
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
22
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
29
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
40
RosuvastatinAstraZenecaPhase 3
40